Effects of Resveratrol Alone or in Combination With Piperine on Cerebral Blood Flow Parameters and Cognitive Performance in Humans
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Northumbria University
- Enrollment
- 23
- Locations
- 1
- Primary Endpoint
- Modulation of levels of total haemoglobin
Study Overview
Brief Summary
Resveratrol is associated with a plethora of physiological effects in humans, including modulation of cerebral blood flow, despite apparently poor bioavailability. This study investigated whether the physiological effects of resveratrol could be affected when co-supplemented with piperine, an alkaloid which may be able to enhance the bioavailability of resveratrol.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Factorial
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 35 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Between the ages of 18-35 years old
- •Non-smoker
Exclusion Criteria
- •Not proficient in English
- •Taking medication or herbal supplements
- •Pregnant or breast feeding
- •Heavy caffeine consumer
- •History of head trauma, migraines, learning difficulties, ADHD, gastrointestinal problems.
- •Food allergies of intolerances
Arms & Interventions
250mg trans- resveratrol
Intervention: Placebo (silica) (Other)
250mg trans-resveratrol with 20mg piperine
Intervention: Placebo (silica) (Other)
Placebo
Intervention: Placebo (silica) (Other)
250mg trans-resveratrol with 20mg piperine
Intervention: Trans- resveratrol (Dietary Supplement)
Placebo
Intervention: Trans- resveratrol (Dietary Supplement)
250mg trans- resveratrol
Intervention: Trans- resveratrol (Dietary Supplement)
Outcomes
Primary Outcomes
Modulation of levels of total haemoglobin
Time Frame: 80 minutes following treatment administration
Modulation of levels of deoxygenated haemoglobin
Time Frame: 80 minutes following treatment administration
Modulation of levels of oxygenated haemoglobin
Time Frame: 80 minutes following treatment administration
Secondary Outcomes
- Number of participants displaying significant modulation of cognitive performance(40-80 minutes post dose)